|
is a Managing Director at Sofinnova Ventures, focused on building successful companies serving medical markets. Prior to joining Sofinnova, Dr. Healy was a partner at Sanderling Ventures where he was the lead or a founding investor in several early stage biomedical companies. He is an author of numerous peer-reviewed scientific publications on the molecular aspects of immune regulation. He has previously held positions at Miles (Bayer) Pharmaceuticals, Lawrence Berkeley Laboratory and Howard Hughes Medical Institute. Dr. Healy is a member of various professional associations and currently serves on the Board of Directors of InterMune Pharmaceuticals, BioSpace.com and other privately-held companies. He received a B.A. in molecular biology and a B.A. in Scandinavian studies from the University of California at Berkeley, where he graduated with highest honors. Dr. Healy completed his M.D. and earned his Ph.D. in immunology from Stanford University School of Medicine. | 